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Abstract
Objective and design To determine the role of interleu-
kin-10 (IL-10) in protecting against the deleterious pro-
inﬂammatory cytokine response to murine cytomegalovirus
(MCMV), we studied the impact of IL-10 repletion in
MCMV-infected IL-10 knockout (KO) mice.
Materials and methods IL-10 KO mice were infected
with a sub-lethal dose of MCMV and treated daily with
5 lg of mouse recombinant IL-10 (mrIL-10). Cytokine
transcription, viral load, cytokine expression and liver
histopathology were assessed in IL-10 treated and
untreated mice.
Results mrIL-10 repletion suppressed the exaggerated
pro-inﬂammatory cytokine response observed in IL-10 KO
mice (vs. control) both systemically and at the organ level,
without affecting viral load. Levels of IFN-c and TNF-a
mRNA in livers of treated mice were *50–70-fold lower
than in untreated mice at day 5 post-infection (p B 0.05).
In spleens and sera, levels of IFN-c and IL-6 were signif-
icantly lower in treated mice than in untreated mice at day
5–7 post-infection (p B 0.05). IL-10 blunting of cytokine
responses was accompanied by attenuation of inﬂammation
in livers of treated mice.
Conclusions Repletion of IL-10 modulates the exagger-
ated pro-inﬂammatory cytokine responses that characterize
IL-10 KO mice and protects against liver damage without
altering viral load. IL-10 may be useful to control dys-
regulated pro-inﬂammatory cytokines responses during
CMV infection.
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Introduction
Interleukin-10 (IL-10) is a pleotrophic, immunomodulatory
cytokine with anti-inﬂammatory and immunosuppressive
properties. An important function of IL-10 is to down-
regulate production of Th1-derived pro-inﬂammatory
cytokines (including IFN-c and TNF-a) and to inhibit
T-cell proliferation [1–3]. Pro-inﬂammatory cytokines are
an essential part of the host response to viral infections. For
example, murine cytomegalovirus (MCMV) infection
induces a pro-inﬂammatory cytokine response character-
ized by production of IFN-c, TNF-a, IL-1a, IL-1b and IL-6
that occurs at the organ level as well as systemically [4–7].
Even though this response is necessary for viral control and
clearance, an excessive production of pro-inﬂammatory
cytokines can also be detrimental to the host and can result
in greater organ damage with increased morbidity and
mortality.
Studies in IL-10 deﬁcient mice have shown that these
mice suffer more severe MCMV disease than do the wild
type background strain. Oakley et al. [8] reported that
IL-10 knockout (IL-10 KO) mice experience more
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sized that this was due to uncontrolled production of pro-
inﬂammatory cytokines, particularly IFN-c and IL-6. In
those experiments, depletion of IFN-c did not reduce the
severity or affect the progression of CMV disease. Other
studies in MCMV-infected IL-10 KO mice showed that
infection of the brain led to lethal disease due to a dys-
regulated production of IFN-c and IFN-c-inducible
chemokines, CXCL9 and CXCL10, as well as IL-6 [9, 10].
Recent studies suggest that IL-10 polymorphisms may
be linked to the risk for human CMV infection after
transplantation and/or to CMV disease severity. Certain
IL-10 genotypes (particularly SNPs at position -1082) are
associated with low or high expression of IL-10 [11].
Alakulppi et al. [12] reported that kidney transplant
recipients with high IL-10 expression genotypes receiving
organs from donors with low IL-10 expression genotypes
did not develop CMV disease, suggesting that the recipient
IL-10 production may be associated with decreased risk of
CMV disease [12].
Furthermore, a number of studies indicate that IL-10
treatment may be therapeutically beneﬁcial in conditions
where pro-inﬂammatory cytokine responses are excessive.
Experimental evidence suggests the therapeutic usefulness
of IL-10 to downregulate inﬂammation in chronic gastro-
intestinal inﬂammatory diseases such as Crohn’s disease
and ulcerative colitis [13, 14]. IL-10 treatment has also
shown beneﬁts in experimental models of autoimmune
diseases including psoriasis, rheumatoid arthritis, and
multiple sclerosis [15–17]. In regards to viral infections,
IL-10 has been used to treat myocarditis induced by
encephalomyocarditis virus (EMCV) and stromal keratitis
caused by herpes simplex virus in mouse models with some
encouraging results [18, 19].
Based on these observations, we hypothesized that IL-10
repletion in MCMV-infected IL-10 KO mice would result
in suppression of pro-inﬂammatory cytokines and conse-
quent reduction of clinical CMV disease. Mouse
recombinant IL-10 (mrIL-10) was administered intraperi-
toneally to MCMV-infected IL-10 KO mice. Our results
showed that IL-10 repletion therapy, as described in this
study, suppressed pro-inﬂammatory cytokines without
altering viral replication, and resulted in some attenuation
of clinical signs of disease and less organ pathology in
MCMV-infected IL-10 KO mice.
Materials and methods
Mice
Pathogen free-female 6–7-week-old IL-10 KO mice were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA). Six to seven-week-old female C57BL/6 mice were
obtained from Harlan Sprague-Dawley (Indianapolis, IN,
USA). All mice were housed in American Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC)-approved speciﬁc pathogen-free (SPF) facili-
ties at our institution and had free access to food and water.
Animal studies and protocols were approved by the Uni-
versity of California, Davis Institutional Animal Care and
Use Committee (IACUC).
Virus and infection
The Smith strain of MCMV was obtained from American
Type Culture Collection (ATCC) (Manassas, VA, USA)
and maintained by salivary gland passage in BALB/c mice.
Salivary gland homogenates (SGV) were prepared in RPMI
1640 (Gibco Laboratories, Grand Island, NY, USA) as
described elsewhere [20]. To determine the sub-lethal dose
to establish a clinical infection, a LD50 of the SVG was
performed using standard protocols [20]. Mice were
infected intraperitoneally (i.p.) with a sub-lethal dose
containing *10
5 plaque forming units (pfu) of MCMV as
determined by the plaque assay [4]. In all studies, controls
(uninfected mice) received the same volume (0.2 ml) of
RPMI i.p. Mice were observed and scored daily for signs of
MCMV disease as follows: 0: no signs observed; ?1:
slightly lethargic, rufﬂe fur primarily around neck, hunched
while sitting; ?2: lethargic, rufﬂe fur around neck area and
torso, backbone prominent when sitting, squinty eyes; ?3:
very lethargic, rufﬂed fur in most areas, red skin around
neck area, hunched when walking, more prominent squinty
eyes.
Mouse recombinant IL-10 treatment of IL-10 KO mice
Carrier-free mouse recombinant IL-10 (mrIL-10) was
obtained from eBioscience (San Diego, CA, USA). mrIL-10
was diluted in phosphate buffer saline (PBS), pH 7.2
(Gibco Laboratories, Grand Island, NY, USA) as recom-
mended by the manufacturer.
Determination of optimal dose of mrIL-10
Various doses of mrIL-10 were initially used to determine
the minimum optimum dose that would allow us to detect
the cytokine in mouse serum by enzyme linked immuno-
assay (ELISA). Doses of 2.5, 5 and 10 lg per mouse per
day were administered intraperitoneally (0.2 ml) to unin-
fected IL-10 KO mice. Serum samples were collected and
analyzed by ELISA at 4 and 20 h after administration of
mrIL-10.
Baseline levels of pro-inﬂammatory cytokines in unin-
fected IL-10 KO mice were very low (IL-1a: 7 pg/ml;
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TNF-a: 4 pg/ml). Repletion of IL-10 in uninfected IL-10
KO mice had no observable impact on baseline levels of
pro-inﬂammatory cytokines or on physiological parameters
in these mice.
Treatment protocol with mrIL-10
IL-10 KO mice were infected with a sub-lethal dose of
MCMV on day 0. mrIL-10 was administered in a dose of
5 lg (0.2 ml, optimum dose) i.p. per mouse per day for ﬁve
consecutive days starting at day 0. Another group of
MCMV-infected IL-10 KO mice received 0.2 ml of PBS
i.p. per day for 5 consecutive days instead of mrIL-10.
Nucleic acid extraction and cDNA synthesis
At days 0, 1, 3, 5 and 8 post-infection, groups of mice
(n = 8) were killed by terminal anesthesia and samples of
livers and spleens were removed and placed in Nucleic
Acid Puriﬁcation Lysis solution (Applied Biosystems,
Foster City, CA, USA) for RNA extraction.
RNA extraction and cDNA synthesis were performed at
the Molecular Core Facility, School of Veterinary Medi-
cine at our institution using the 6700 RNA extraction
apparatus (Applied Biosystems, Foster City, CA, USA) as
described elsewhere [5]. DNA was extracted from each
organ with the DNeasy Tissue Kit (Qiagen, Valencia, CA,
USA) following the manufacturer’s instructions.
Cytokine and chemokine transcription in target organs
using real-time PCR
Transcription of IL-1a, IL-1b, IL-6, IFN-c, TNF-a, and
CXCL9 and CXCL10, as well as transcription of the
housekeeping genes GAPDH and HPRT, was determined
by quantitative real-time PCR (qRT-PCR) using the Assay
on Demand kits (Applied Biosystems, Foster City, CA,
USA) with the respective primers/ﬂuorogenic probe mix
speciﬁc for each cytokine/chemokine gene. Brieﬂy, real-
time PCR reactions were set up in duplicate for each of the
cytokines, chemokines and housekeeping genes in each
organ. Ampliﬁcation conditions were identical for all
reactions and consisted of 2 min at 50C, 10 min at 95C
and 40 cycles of 15 s at 95C and 60 s at 60C. All reac-
tions were prepared in a ﬁnal volume of 6 ll consisting of
3.5 ll of Universal Master mix (Applied Biosystems,
Foster City, CA, USA) containing the respective primer/
probe mix and 2.5 ll of cDNA. Ampliﬁcations were done
in 384-well plate format in an ABI Prism 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA).
Final quantiﬁcation was performed using the compara-
tive CT method as described [5, 21]. In brief, for each
experimental sample, the difference between the target CT
value and the CT value of the most stable housekeeping
gene for each tissue type was used to normalize for dif-
ferences in the amount of total nucleic acid added to each
reaction and the efﬁciency of the RT step (DCT). For rel-
ative quantiﬁcation by the comparative CT method, values
are then expressed relative to a reference sample called the
calibrator, which is the weakest signal from the normali-
zation (DCT) in each tissue type. The DCT from each
experimental sample was subtracted from the DCT of the
calibrator (DDCT). The amount of target (linear value)
normalized to an internal control or housekeeping gene and
relative to the calibrator was determined by 2
DDC
T. Linear
expression in each tissue represents the linear expression
value of each gene in infected mice minus that in unin-
fected mice (baseline or day 0).
Assay of cytokine levels in sera of IL-10 KO mice
by ELISA
At the time points indicated above, blood was collected by
cardiac puncture and allowed to clot, and serum was col-
lected by centrifugation and stored at -20C. Serum levels
of IL-1a, IL-1b, IL-6, IL-10, IFN-c, and TNF-a were
assayed using the 6-Plex Mouse Cytokine Panel in a
Bioplex plate reader (BioRad Laboratories, Hercules, CA,
USA). Assays were performed in duplicate on serum
samples from eight mice per time point. All assays were
performed following the manufacturer’s recommendations.
Assay of viral load in target organs by quantitative real
time PCR and plaque assay
MCMV viral load was quantiﬁed as previously described
[5]. Ampliﬁcation and cloning of the MCMV immediate
earlygene1(IE-1),sequencesoftheprimersandﬂuorogenic
probe, ampliﬁcation conditions and ﬁnal quantiﬁcation are
described elsewhere [5]. Plaque assays were performed
using standard protocols as previously described [4].
Liver histopathology
Samples of livers and spleens were ﬁxed in 4% parafor-
maldehyde in PBS and parafﬁn embedded using standard
protocols. Six micrometer thick parafﬁn embedded sections
of livers and spleens were deparaﬁnized and hydrated
through graded alcohol washes. Hematoxylin and Eosin
(H&E) staining of parafﬁn-embedded sections of livers and
spleens from MCMV infected IL-10 KO and C57BL/6
mice were done according to standard protocols. The
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score liver pathology (Table 1)[ 22, 23].
Statistical analyses
To compare the cytokine response and viral load between
mrIL-10 treated and untreated mice, two sample t tests
were used separately for each cytokine in each organ at
each of the time points analyzed; 95% conﬁdence intervals
for the difference in means were calculated. Data were
plotted to check for normality and non-parametric alter-
native procedures (Wilcoxon rank sum test) were carried
out if the data suggested possible violations of distribution
assumptions after log transformation. Results were con-
sidered statistically signiﬁcant when p B 0.05. Analyses
were performed using SAS Version 9.1 (SAS) statistical
software.
Results
Determination of mrIL-10 levels in serum of IL-10 KO
mice
To determine the time course for systemic distribution of
IL-10 and the optimum dose to use in our studies, unin-
fected IL-10 KO mice were treated with various doses of
mrIL-10 and serum levels of IL-10 were assessed at 4 and
20 h after treatment. Signiﬁcant levels of IL-10 were
detectable in sera of mice receiving 2.5, 5 and 10 lgo f
mrIL-10after4 h(averageof3,457,9,705and20,152 pg/ml,
respectively, for each dose). By 20 h post-treatment,
systemic levels of IL-10 had decreased 100 to 1,000-fold
but were still detectable in mice receiving 5 and 10 lgo f
mrIL-10 (Table 2). Based on these results, all subsequent
experiments were performed using a dose of 5 lg of mrIL-
10 for 5 days starting on day 0 (day of infection).
Pro-inﬂammatory cytokine and chemokine
transcription in livers and spleens of IL-10 KO mice
treated with mrIL-10 was reduced at day 5
post-infection compared to untreated mice
We hypothesized that repletion of IL-10 in MCMV-infec-
ted IL-10 KO mice would inhibit pro-inﬂammatory
cytokines and thus suppress target organ inﬂammation and
tissue damage. Transcription studies using quantitative
real-time PCR showed comparable cytokine levels at day 1
(Fig. 1a). By day 3, pro-inﬂammatory cytokine mRNA
levels in livers of MCMV-infected IL-10 treated mice were
signiﬁcantly lower than in untreated mice (Fig. 1b). A
signiﬁcant decrease in IFN-c (*70-fold) and TNF-a
(*50-fold) mRNA was observed in livers of the MCMV-
infected, IL-10 treated mice compared to untreated mice at
day 5 post-infection (p B 0.05) (Fig. 1c). By day 8 post-
infection, and after IL-10 treatment was discontinued,
transcription patterns in livers were similar in treated and
untreated groups (Fig. 1d).
In spleens, comparable pro-inﬂammatory cytokine
transcription was observed in treated and untreated mice at
days 1 and 3 post-infection (Fig. 2a, b). However, by day 5
post-infection, mRNA transcripts of IFN-c were *17-fold
and of IL-6 were *600-fold lower in spleens of MCMV-
infected, IL-10 treated compared to the untreated mice
(p\0.05) (Fig. 2c). Pro-inﬂammatory cytokine transcrip-
tion remained lower in spleens at day 8 post-infection,
particularly IL-1a (p\0.005) (Fig. 2d).
Transcription of IFN-c-inducible chemokines CXCL9
and CXCL10 mRNA was *4 to 6-fold lower in livers
of MCMV-infected, IL-10 treated mice at days 3 to 5
post-infection (p\0.005) (Fig. 3 a, b), and *4 to 6-fold
lower in spleens at day 5 post-infection (p B 0.005)
(Fig. 3c, d).
As previously reported, pro-inﬂammatory cytokines
were produced in response to MCMV infection in the
Table 1 Liver Histology Activity Index (HAI) [22]
Periportal ± bridging necrosis Intralobular degeneration
and focal necrosis
Portal inﬂammation Fibrosis
0 = None 0 = None 0 = None 0 = None
1–2 = Mild piecemeal necrosis 1–2 = Mild (involves\1/3
of lobules or nodules)
1–2 = Mild (sprinkling of
inﬂammatory cells in\1/3
of portal tracts)
1–2 = Fibrous
portal expansion
3 = Moderate piecemeal necrosis (involves\50%
of the circumference of most portal tracts)
3 = Moderate (involvement
of 1/3–2/3 of lobules or nodules)
3 = Moderate (increased
inﬂammatory cells in 1/3-2/3
of portal tracts)
3 = Bridging
ﬁbrosis
4 = Marked piecemeal necrosis (involves[50%
of the circumference of most portal tracts)
4 = Marked (involvement
of[2/3 of nodules)
4 = Marked (dense packing
of inﬂammatory cells in[2/3
of portal tracts)
4 = Cirrhosis
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induced transcription of IFN-c, TNF-a and IL-6 starting
at day 2 post-infection, which remained elevated
until day 5 post-infection, but cytokine levels were
signiﬁcantly lower than in IL-10 KO mice (data not
shown).
Serum levels of pro-inﬂammatory cytokines in IL-10
KO mice treated with mrIL-10 were lower at day 5
post-infection compared to untreated mice
Comparable levels of serum cytokines were detected in
MCMV-infected IL-10 treated and untreated mice at days 1
Table 2 Concentration (pg/ml) of mrIL-10 in sera of IL-10 KO mice receiving various doses of mrIL-10
Time after IL-10 injection Dose: 2.5 lg Dose: 5 lg Dose: 10 lg
4 h 3,457 (±659) pg/ml 9,705 (±4,127) pg/ml 20,152 (±6,246) pg/ml
20 h \11 (±4) pg/ml 90 (±77) pg/ml 285 (±318) pg/ml
Four IL-10 KO mice were used per time point/per dose
Fig. 1 Cytokine transcription
in livers of treated and untreated
MCMV-infected IL-10 KO
mice at a 1 day post-infection;
b 3 days post-infection;
c 5 days post-infection;
d 8 days post-infection. Data
represent average of 8 mice per
time point. Linear
value = linear value in
infected - linear value in
uninfected control mice;
*statistically signiﬁcant
difference between treated
versus untreated mice
represented as p B 0.05
(Wilcoxon rank sum test)
Fig. 2 Cytokine transcription
in spleens of treated and
untreated MCMV-infected
IL-10 KO mice at a 1 day
post-infection; b 3
days post-infection; c 5 days
post-infection; d 8 days
post-infection. Data represent
average of 8 mice per time
point. Linear value = linear
value in infected - linear value
in uninfected control mice;
*statistically signiﬁcant
difference between treated
versus untreated mice
represented as p B 0.05
(Wilcoxon rank sum test)
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infection, serum levels of IFN-c were signiﬁcantly lower
(*10-fold) in the IL-10 treated compared to the untreated
IL-10 KO mice (p\0.05) (Fig. 4).
MCMV viral load was similar in mrIL-10 treated
versus untreated IL-10 KO mice
In order to determine if IL-10 treatment had an effect on
MCMV, we quantiﬁed MCMV IE-1 gene copies in livers
and spleens of treated and untreated mice using quantita-
tive real time PCR, as well as viral replication using plaque
assay (pfu). Viral loads in both groups of mice peaked at
day 3–5 post-infection, with comparable amounts of IE-1
gene sequences in livers and spleens of both treated and
untreated mice (Fig. 5). Viral replication studies using
plaque assay conﬁrmed the comparable viral load results
(data not shown).
MCMV-induced weight loss and liver pathology
in mrIL-10 treated versus untreated IL-10 KO mice
Untreated IL-10 KO mice showed a trend toward suffering
increased MCMV-induced weight loss compared to mice
repleted with mrIL-10 (Fig. 6). By day 3–5 post-infection,
percent weight loss was 14% in the untreated mice com-
pared to 10% in the IL-10 KO repleted mice (p = 0.08).
Other clinical signs of CMV disease (lethargy, rufﬂed fur
and hunched posture) were similar in both groups of mice
(score of ?1).
At day 3 post-infection, more pronounced intralobular
degeneration and focal necrosis was observed in livers of
untreated versus IL-10 treated mice (p = 0.04) (Fig. 7a, b,
d, e) (Table 3). In addition, we observed a trend for lym-
phocyte inﬁltration to be greater (*2-fold) in livers of
untreated versus treated mice at day 5 post-infection
(p = 0.09) (Fig. 7c, f). No pathological ﬁndings were
observed in spleens of either group of mice (data not
shown).
Discussion
IL-10 deﬁcient mice have increased morbidity from
MCMV infection compared to the background strain,
Fig. 3 Transcription of CXCL9
and CXCL10 in livers and
spleens of MCMV-infected IL-
10 treated and untreated IL-10
KO mice. a, b transcription in
livers; c, d transcription in
spleens. Data represent average
of 8 mice per time point. Linear
value = linear value in
infected - linear value in
uninfected control mice;
*statistically signiﬁcant
difference between treated
versus untreated mice
represented as p B 0.05 (two
sample t test)
Fig. 4 Cytokine levels in sera of MCMV-infected IL-10 treated and
untreated IL-10 KO mice at day 5 post-infection. Data represent
average of 8 mice per time point; *statistical signiﬁcant difference
between treated and untreated mice represented as p B 0.05 (two
sample t test)
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of IL-10, an exaggerated production of pro-inﬂammatory
cytokines, particularly IFN-c and IL-6, rather than
increased viral replication, might be responsible for the
exacerbated severity of CMV disease. To test this
hypothesis, we treated MCMV-infected IL-10 KO mice
with IL-10 to see if repletion would inhibit pro-inﬂam-
matory responses and what the impact would be on viral
load and clinical evidence of CMV disease. We found that
the administration of exogenous mrIL-10 over a 5-day
period, starting on the day of infection, suppressed IFN-c,
TNF-a and IL-6 transcripts in target organs, reduced sys-
temic levels of IFN-c and IL-6 and decreased production of
the IFN-c inducible chemokines CXCL9 and CXCL10 but
did not affect MCMV viral load. We also observed bene-
ﬁcial effects of IL-10 repletion on liver pathology with
decreased focal necrosis in the liver at day 3 post-infection.
Our ﬁndings conﬁrmed our hypothesis that IL-10 repletion
in our mouse model of MCMV infection blunts pro-
inﬂammatory cytokine responses without impacting viral
replication.
The therapeutic use of IL-10 in auto-immune and
inﬂammatory diseases has been controversial, with many
studies in mouse models showing a beneﬁcial effect [15,
17, 24], but others reporting conﬂicting results [16]. These
discrepancies may be attributable to differences in the
dose, source, mode and route of delivery of IL-10. In our
study, we administered 5 lg of murine recombinant IL-10
daily for 5 days by intraperitoneal injection. Levels of IL-10
were detectable in sera of treated mice 20 h after injection,
but they were *100-fold lower than initial levels. Our
treatment protocol resulted in a signiﬁcant reduction of
pro-inﬂammatory cytokines (both systemically and at the
organ level), particularly after ﬁve treatments (day 5 post-
infection). The lack of a sustained, continuous and regu-
lated dose of IL-10 during the course of MCMV infection
may explain the mild effect of IL-10 on disease severity
observed in this study. Studies are in progress in our lab-
oratory using IL-10 expression vectors to deliver sustained
and controlled doses of IL-10 in our IL-10 deﬁcient mouse
model to determine if a more dramatic impact on clinical
disease severity can be demonstrated.
Despite suppressing pro-inﬂammatory cytokines, exog-
enous mrIL-10 did not affect viral replication. Pro-
inﬂammatory cytokines are part of the host response to
CMV infection and participate in viral clearance. The
ﬁnding that viral load was comparable in both groups of
mice suggest that IL-10, as used in this study, does not
impair the control of CMV, but rather may inhibit local
production of pro-inﬂammatory cytokines by inﬁltrating
lymphocytes in target organs. Our results are in accord with
the observations of Nishio et al.[18], that IL-10 treatment
of viral myocarditis induced by EMCV suppressed
inﬂammation without altering viral replication, and of
Cheeran et al. [9], who reported similar MCMV viral loads
in IL-10 deﬁcient mice and in immunocompetent mice,
C57BL/6 (which is a model simulated by the IL-10 KO
mice repleted with mrIL-10).
Importantly, when considering possible therapeutic use
of IL-10 to achieve these beneﬁts, our results demonstrated
that IL-10 did not increase MCMV replication in target
Fig. 5 Viral load (IE1 gene
copies) in livers (a) and spleens
(b) of MCMV-infected IL-10
treated and untreated IL-10 KO
mice. Data represent average of
8 mice per time point. No
signiﬁcant differences were
observed in treated versus
untreated mice
Fig. 6 Weight loss in MCMV-infected IL-10 treated and untreated
IL-10 KO mice. Data represent average of 8 mice per time point
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organs. This is in contrast to reports with other viral
infections in which IL-10 treatment was associated with
viral persistence. Such studies include lymphocytic chori-
omeningitis virus (LCMV) in mice [25] and HIV and
hepatitis C (HCV) in humans [26, 27]. On the other hand,
some previous studies of other viruses parallel our results,
such as the studies of Lin et al. [28] using a neurotrophic
strain of mouse hepatitis virus. Lin et al. showed that
clearance of the virus in IL-10 deﬁcient and C57BL/6
immunocompetent mice occurred with equal kinetics, and
that IL-10 did not delay viral clearance during acute
encephalomyelitis with mouse hepatitis virus. Thus, it is
likely that the impact of IL-10 on viral load is virus-speciﬁc
and disease-model speciﬁc.
CMV infection is a trigger of pro- inﬂammatory cyto-
kines and is an identiﬁed risk for graft versus host disease
(GVHD) and organ rejection after transplantation. The role
that IL-10 plays during CMV infection in transplant
recipients is still being actively explored. CMV replication
in renal transplant recipients has been associated with
increased levels of IL-10 and decreased IFN-c plasma
levels [29]. Nordoy et al. [30] showed that CMV infection
in renal transplant recipients is characterized by a persistent
activation of TNF-a in symptomatic CMV positive
patients, while CMV-infected, asymptomatic patients had
elevated levels of IL-10. TNF-a is a key factor in reacti-
vating CMV from latency leading to expression of CMV
immediate early gene and viral replication [31]. Thus, the
balance between TNF-a and IL-10 may be an important
factor in the development of clinical disease [30]. Yet, in
lung transplant recipients, a prolonged delayed in clearance
of HCMV has been associated with elevated levels of
IL-10 [32]. Clearly, it is important to distinguish the role of
Fig. 7 H&E stained sections of
livers from a MCMV-infected
untreated mice at day 3 post-
infection (109); b MCMV-
infected untreated mice at day 3
post-infection (209); c MCMV-
infected untreated mice at day 5
post-infection (209); d MCMV-
infected, IL-10 treated mice at
day 3 post-infection (109);
e MCMV-infected, IL-10
treated mice at day 3 post-
infection (209); f MCMV-
infected, IL-10 treated mice at
day 5 post-infection (209).
Sections are representative of 8
mice per time point. Number of
inﬂammatory foci was increased
in the untreated mice (a–c)
240 Y. J. Tang-Feldman et al.IL-10 in risk of acquiring initial infections versus its
production in response to viral-induced pro-inﬂammatory
cytokines as well as its role in limiting disease severity.
The signiﬁcant increase in intralobular degeneration and
focal necrosis in the livers of untreated IL-10 deﬁcient
mice at day 3 post-infection correlated with increases in
CXCL9 transcripts in livers. CXCL9 and CXCL10 are
chemokines involved in promoting T lymphocyte migra-
tion into the liver and have been correlated with hepatic
accumulation of MCMV-speciﬁc CD8 T-cells [33]. In
CMV infected human microgial cells, IL-10 treatment
inhibited production of CXCL10 by these cells [34]. We
demonstrated that repletion of IL-10 suppresses CXCL9
and CXCL10 production in livers and spleens of MCMV-
infected mice. The ﬁnding of more severe pathological
changes, in the absence of IL-10, in the livers of untreated
mice at day 3 post-infection suggests that over-expression
of CXCL9 and CXCL10 chemokines resulting in an inﬂux
of lymphocytes may have been responsible for the pro-
duction of pro-inﬂammatory cytokines and consequent
tissue damage.
Thus, in our study, we showed that early repletion
(starting at the time of infection) of IL-10 in IL-10 deﬁcient
MCMV-infected mice has beneﬁcial effects in control of
inﬂammatory cytokines and chemokines, suppressing pro-
duction of IFN-c, TNF-a, IL-6, and the IFN-c- inducible
chemokines CXCL9 and CXCL10. These ﬁndings suggest
that immunomodulatory therapy with IL-10 may be useful
in preventing or reducing CMV disease severity in high
risk patients.
Repletion of IL-10 may be a beneﬁcial immunothera-
peutic approach prior to or during organ transplantation.
Pre-treatment of lungs (prior to transplantation) with IL-10
has been shown to improve lung function and reduce
inﬂammation [35]. Regulated IL-10 expression inhibits
cardiac allograph vasculopathy, reducing the number of
graft-inﬁltrating lymphocytes and macrophages and pre-
venting chronic rejection of transplanted hearts [36].
Similarly, an association has been found between the level
of pre-transplant IL-10 production and development of
acute GVHD (aGVHD) in allogeneic stem cell transplan-
tation, with increased levels of IL-10 correlating with low
incidence of aGVHD [37, 38]. Additionally, overproduc-
tion of IL-10 has been linked to the development of
tolerance in severe combined immunodeﬁcient patients
transplanted with HLA mismatched hematopoietic stem
cells [37, 39], and high levels of IL-10 have been associ-
ated with induction and maintenance of tolerance after
allogeneic stem cell transplantation [39]. Thus, our study
extends the reports suggesting the use of IL-10 as a
potential tool to treat inﬂammatory conditions, including
viral infections in which an exaggerated pro-inﬂammatory
cytokine response has detrimental end-organ effects. Fur-
thermore, IL-10 treatment early during the at-risk period
may be an important therapeutic approach to explore for
transplant and other immunocompromised patients with
IL-10 polymorphisms resulting in under-expression of
IL-10.
In conclusion, we found that administration of exoge-
nous mrIL-10 to replete cytokine levels in IL-10 KO mice
modulates pro-inﬂammatory cytokine responses to MCMV
infection at the organ level and systemically, independent
of an effect on viral load. Our studies expand the current
understanding of the role of IL-10 in CMV infection
demonstrating that IL-10 is a key regulatory cytokine with
immunotherapeutic properties, and raise the possibility that
Table 3 Average histopathology scores in livers of MCMV-infected IL-10 treated and untreated IL-10 KO mice
Sample and day of treatment Periportal ± bridging
necrosis score
Intralobular degeneration
and focal necrosis score
Portal inﬂammation
score
Fibrosis
score
Day 1
MCMV alone 0 0 0 0
MCMV ? IL-10 0 0 0 0
Day 3
MCMV alone 2 3 2 0
MCMV ? IL-10 1.5 (p = 0.14) 1.5 (p = 0.04) 1 (p = 0.07) 0
Day 5
MCMV alone 2.2 2.2 2.2 0
MCMV ? IL-10 2 (p = 0.19) 2 2 0
Day 8
MCMV alone 1.5 1.7 1.5 0
MCMV ? IL-10 1 (p = 0.09) 1.5 (p = 0.39) 1 (p = 0.09) 0
Scores represent average of pathological lesions in n = 8 mice per each treatment group (See Table 1 for description of histopathological
ﬁndings) with statistical signiﬁcance represented as p = 0.04 at day 3 (two tailed t test) between mrIL-10 treated and untreated mice
Interleukin-10 repletion suppresses pro-inﬂammatory cytokines 241the administration of this cytokine may be useful to control
dysregulated pro-inﬂammatory responses during CMV
disease. Studies are in progress in our laboratory to deﬁne
molecular mechanisms by which IL-10 exerts its anti-
inﬂammatory effect during MCMV infection.
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